In today's Morning Views publication we comment on developments of the following high yield issuers: Applus, Verisure, CeramTec, Kiloutou, Odido, Eolo, Flora Food Group, Altice France (SFR), evoke, FiberCop, Tele Columbus, Engineering Group, Altice International, Intralot, Mehilainen, Itelyum Group, Voyage Care, Grupo Antolin, Benteler International, Neopharmed, Cheplapharm, Industria Macchine Automatiche, Allwyn (formerly Sazka), Victoria, Best Secret, Softbank Group, Profine, Bombardier, Grune...
In today's Morning Views publication we comment on developments of the following high yield issuers: Playtech, Guala Closures, evoke, Grupo Antolin, Nokia, NES Fircroft, MasOrange, Paprec Group, Biofarma, Vallourec, Forvia (formerly Faurecia), Ineos, Ineos Quattro
In today's Morning Views publication we comment on developments of the following high yield issuers: Mahle, Guala Closures, Playtech, Grupo Antolin, NewDay, Kiloutou, David Lloyd Leisure, Omnia Technologies, Cirsa, evoke, Derichebourg, Seche Environnement, Samvardhana Motherson, Teva
evoke published strong H1/25 results yesterday, with sales up 3% y-o-y and adjusted EBITDA growing 44%. FCF also improved, but remained negative. Net leverage fell 0.7x from FYE 2024 at 5.0x. The company reiterated its FY 2025 guidance. We expect EBITDA growth and further deleveraging in FY 2025.
The Europe HY Trade Book for May 2025 includes current trade recommendations drawn from our European HY coverage universe, along with relative-value scatter plots and tables by industry. We also discuss the US tariff situation and key related impacts.
In today's Morning Views publication we comment on developments of the following high yield issuers: CeramTec, evoke, SPIE, Fedrigoni, Odido, Profine, Infopro Digital, Banijay, Neopharmed, Vedanta Resources, Nemak, CMA CGM, Ineos, Ineos Quattro, Flos B&B Italia (formerly International Design Group)
evoke published its FY 2024 results yesterday, with slightly better performance compared to the full-year trading update released in January 2025. FY 2024 sales grew by 3% y-o-y, while adjusted EBITDA rose 4%. FCF strengthened y-o-y, while reported net leverage was 5.7x, improved from 5.9x as of FYE 2023. We expect the company to deliver EBITDA growth and deleverage in FY 2025.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.